Conjoint analysis with integrated order of entry assessment, preceded by qualitative market landscaping and TPP assessment to inform the conjoint design
KEY PROJECT PERSONNEL
Lisa Heideman and Alison Golding are Directors with gold standard expertise in complex quantitative techniques; they love to inform business decisions in areas of high complexity or novelty
2 months for the qualitative stage, 3 months for the quantitative phase
Gene therapy is a new paradigm in hemophilia. Our client’s gene therapy is expected to be second or third to market, but with a stronger clinical profile. However, once treated with any competitor gene therapy, patients become permanently ineligible for our client’s product.
Blueprint Partnership developed an excel-based simulator that integrates conjoint simulations with order of entry and uptake curves to max product potential.